Zoetis Inc. (NYSE:ZTS) Receives $221.44 Consensus Target Price from Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have earned a consensus rating of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $221.44.

A number of brokerages recently weighed in on ZTS. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th.

Zoetis Stock Up 0.6 %

Shares of Zoetis stock opened at $176.74 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market cap of $79.74 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 2.74 and a beta of 0.90. The firm’s 50-day moving average is $184.51 and its two-hundred day moving average is $180.81. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company posted $1.36 earnings per share. As a group, research analysts expect that Zoetis will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio is currently 32.33%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Mizuho Securities USA LLC lifted its position in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the period. Sarasin & Partners LLP boosted its stake in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares during the last quarter. Swedbank AB acquired a new stake in Zoetis during the first quarter worth about $210,815,000. International Assets Investment Management LLC raised its position in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after acquiring an additional 937,700 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Zoetis by 7,608.6% in the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after purchasing an additional 824,843 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.